P. Mounika*, T. Malyadri, P. Sreenivasa Prasanna and K. Thejomoorthy


Teriflunomide is used to treat multiple sclerosis-MS. It is not a cure for MS but is thought to work by decreasing certain immune system cells (lymphocytes) which can attack the nerves in your brain and spinal cord. This helps decrease the number of flare-ups (relapses) and may help slow down physical problems caused by MS. Teriflunomide is a BCS class II drug having low solubility and high permeability, so to increase its solubility Teriflunomide is formulated as a Nanosuspension. Nanosuspension is a novel technique used to increase the solubility of the drug prepared by Solvent evaporation method. The present trend of pharmaceutical research lies in the usage of biodegradable polymer because of its availability and low toxicity. Nanosuspension containing drug was prepared by solvent evaporation method by using SLS, Polaxomer, PVP K30, PVA and acetone as organic solvent. The Nanosuspension were evaluated for parameters such as Entrapment efficiency, scanning electron microscopy, particle size analysis, zeta potential, in-vitro release, drug excipient interactions (FTIR). The entrapment efficacy of the formulated Nanosuspension was found to be in the range of 79.52%- 92.16% respectively. Zeta potential value for the optimized formulation (F3) was found to be within the acceptable limits. Average particle size of nanosuspension of optimized formulations (F3) was found to be 489.7nm. From the invitro studies we can say that formulation F3 shows best drug release of 99 % within 45 minutes where as all the other formulations takes about 60-180 minutes to release the drug. Based on the regression values it was concluded that the optimized formulation F3 follows Zero order kinetics.

Keywords: Teriflunomide, Nanosuspension, SLS, Polaxomer, PVP K30, PVA.

[Full Text Article]


Forgot Password  |  Register


Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Dr. Dhrubo Jyoti Sen

Download Article : Click here

News & Updation


    AUGUST 2022 Issue has been successfully launched on 1 August 2022.

  • EJBPS New Impact Factor

    Its our Pleasure to Inform you that EJBPS Impact Factor has been increased from 5.467 to 6.044, due to high quality Publication at International Level.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.


UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS


Copyright From

Covering Letter

                        Author Instruction